Creative Biomart Blog

Mon, 2024/06/03

Phase I Research Data on Bispecific IgG Degradation Agents Released

Biohaven has released Phase I data for its IgG degrading agent BHV-1300 and stated that BHV-1300 rapidly and selectively reduces IgG in a dose-dependent manner. BHV-1300 is a bispecific protein degrading agent under research, and its mechanism of action is to search for and bind with pathogenic IgG, bringing it to the liver for degradation. This gives BHV-1300 the potential to treat antibody-driven diseases such as rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus. Preliminary Phase I data shows that some patients have IgG concentrations as low as 50% to 70% o

Sat, 2024/04/27

The Key Role of HIF-1Α in Promoting the Activation of Embryonic Zygotic Genome

The development of normal mammals occurs in a hydrogen-peroxide environment, and the adaptive response to hydrogen peroxide is considered a landmark event for embryo survival in hypoxic fallopian tubes and intrauterine environments, thus playing a crucial role in mammalian evolution. Due to the gene deletion of hypoxia-inducible factor (HIF) (oxygen-sensitive transcription factor), the response to physO2 is insufficient, resulting in embryo loss during implantation or severe developmental defects shortly after implantation. However, due to significant morphological defects occurring mainly dur

Sat, 2024/04/27

The Gasdermin Family: Emerging Therapeutic Targets for Diseases

The recently discovered Gasdermin (GSDM) protein family plays a crucial role in regulating pyroptosis, a special form of programmed cell death (PCD). In humans, six homologous genes have been identified: GSDMA-E and DFNB59. The role of GSDMs in pyroptosis has been confirmed, and GSDMA-E has been shown to undergo protein hydrolysis processing, leading to the release of n-terminal (NT) fragments that assemble into pores on the plasma membrane (PM). These GSDM pores can penetrate PM and mitochondrial membranes, leading to inflammatory cell death. In addition, they promote the extracellular sec

Fri, 2024/04/26

QDPR Deficiency Leads to Immunosuppression of Pancreatic Cancer

The research team led by Lin Dongxin, Zheng Jian, and Wang Liqin from the Cancer Prevention and Treatment Center of Sun Yat-sen University and the National Key Laboratory of Malignant Tumor Prevention and Treatment in South China published a research paper titled "QDPR deficiency drives immune suppression in pancreatic cancer" in the Cell Metabolism journal. This study found that in pancreatic ductal adenocarcinoma (PDAC), quinone dihydropterin reductase (QDPR) deficiency leads to immunosuppression of pancreatic cancer. QDPR deficiency leads to resistance to immune checkpoint blockade (ICB)

Fri, 2024/04/26

Key Targets in Molecular Characteristics of Parkinson's disease at Different Stages of Progression

The neuroinflammation associated with Parkinson's disease (PD) has attracted widespread attention due to abnormal protein aggregation, among which glycosylation, as a post-translational modification process that maintains protein stability, plays an important role in this process. Recently, in a research report published in the international journal PNAS Nexus titled " Changes in tissue protein N-glycosylation and associated molecular signature occur in the human Parkinsonian brain in a region-specific manner", scientists from institutions such as the University of Galway identified for the

Fri, 2024/04/26

FOXO1- Key Protein That Can Control the Lifespan of Car-T Cells

Nowadays, CAR-T cell therapy has completely changed the treatment of certain types of cancer. The longer these CAR-T cells survive in the patient's body, the more effective their response to cancer becomes. Recently, a research report titled "FOXO1 is a master regulator of memory programming in CAR T cells" was published in the journal Nature. Scientists from institutions such as Stanford University School of Medicine found through their research that a unique protein called FOXO1 can enhance the survival and function of CAR-T cells, indicating the potential for developing more efficient CA

Fri, 2024/04/26

A New Study Has Successfully Constructed a Human Neuron Model That Simulates the Diffusion of Tau Protein Aggregates

In a new study, researchers from the Will Cornell School of Medicine in the United States have developed an innovative human neuron model that can effectively simulate the diffusion of tau protein aggregates in the brain - a process that is responsible for cognitive decline in Alzheimer's disease and frontotemporal dementia. Through this new model, they discovered novel therapeutic targets that may prevent tau diffusion. This preclinical study is a significant advancement in Alzheimer's disease research. The relevant research results were published online in the Cell, under the title "Human iP

Fri, 2024/04/26

A New Mechanism of Glucocorticoid Inhibition of Inflammation

Cortisone and other related glucocorticoids are highly effective in inhibiting excessive immune responses. But before this, people knew very little about how they did it. Now, in a new study, researchers from Berlin's Charlotte Medical School, the University of Erlangen, and the University of Ulm have conducted a more detailed exploration of their molecular mechanisms of action. They report that glucocorticoids can reshape the metabolism of immune cells, activating the body's natural "brakes" on inflammation. These findings lay the foundation for the development of anti-inflammatory drugs w